CAS: 630-60-4; Ouabain

该化合物是非洲植物Strophenthus的种子所产的心脏胶质,已知它对心血管系统有重大影响,主要是作为纳+/K+ATPase酶酶抑制剂的作用,这种抑制导致细胞内钠含量增加,随后通过钠-钙交换器增加钙的流入,导致心肌萎缩程度增加.Ouabain的特点是它能够提高心率和耐受性,使其在某些医疗条件下有用,尽管由于潜在的毒性和副作用,该化合物的使用有限.该化合物通常在受控制的环境中管理,如果不认真监测,可能导致心律和其他心血管并发症.此外,还研究了Ouabain在各种生理过程的潜在作用及其对细胞信号路径的影响.其结构上有一个带有糖性细胞细胞细胞的类固核,有助于其生物活动.

结构式图片

欧盟法规

统一分类与标签压力设备指令-第1组危险流体ECHA物质ECHA物质工作场所安全标识要求C&L通报REACH预注册废弃物危险特性清单

上下游产品

CAS号508-52-1 烏巴配基

合成工艺路线路线简述

    (2R,3R,4R,5S,6S)-2-(((1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-11-Acetoxy-1,5,14-Trihydroxy-10-(Hydroxymethyl)-13-Methyl-17-(5-Oxo-2,5-Dihydrofuran-3-yl)Hexadecahydro-1H-Cyclopenta[a]Phenanthren-3-yl)Oxy)-6-Methyltetrahydro-2H-Pyran-3,4,5-Triyl Tribenzoate置于sodium Carbonate体系中,用 甲醇 作为反应溶剂,化学反应 1.0H,以88%的收率获得产物g毒毛旋花苷
    参考文献:瓦巴加宁和哇巴因的全合成.
    标题:瓦巴加宁和哇巴因的全合成.
    摘要:
    DOI:10.1002/anie.200704959

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-6362009-B1
    优先权日:1997-11-21
    标 题 :Solid phase synthesis of heterocycles
    发明人:MUNOZ BENITO; CHEN CHIXU
    权利人:MERCK & CO INC
    摘要:Methods for solid phase and combinatorial synthesis using a resin activation/capture approach are provided. In particular, methods for the production of dihydropyridones, N-acyidihydropyridones, tetrahydropyridones, pyridines, aminopyridines, N-acyltetrahydropyridines and tetrahydropyridines compounds and libraries containing such compounds are provided. Methods for screening the libraries and compounds and pharmaceutical compositions containing compounds prepared by the methods are provided.

    专利号:US-2005080260-A1
    优先权日:2003-04-22
    标 题 :Preparation of prodrugs for selective drug delivery
    发明人:MILLS RANDELL L; WU GUO-ZHANG
    摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

    专利号:US-4761413-A
    优先权日:1986-12-22
    标 题:1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins and use in treatment of ulcers
    发明人:WACHTER MICHAEL P; KARANEWSKY DONALD S
    权利人:ORTHO PHARMA CORP
    摘要:The synthesis of epoxybenzazepin compounds is described. The novel compounds have anti-ulcer activity.

    专利号:US-4855426-A
    优先权日:1986-12-22
    标题:Process of preparing 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins
    发明人:WACHTER MICHAEL P; KARANEWSKY DONALD S
    权利人:ORTHO PHARMA CORP
    摘要:The synthesis of epoxybenzazepin compounds is described. The novel compounds have anti-ulcer activity.

    专利号:US-5519131-A
    优先权日:1991-04-15
    标题:Synthesis of pyridooxazinyl-indoles
    发明人:EFFLAND RICHARD C; DAVIS LARRY; OLSEN GORDON E
    权利人:HOECHST MARION ROUSSEL INC
    摘要:This application relates to a process for the preparation of indolylpyridooxazines of the formula wherein R1, R2 and R3 are as defined in the specification which comprises cyclizing compound of the formula in the presence of a strong base such as sodium hydride or potassium t-butoxide.
    聊城金信达新材料有限公司
    小微企业
    信用代码: 91371500MAC9RFKF58法定代表人:刘承良
    注册资本:2,00万(元)企业类型:有限责任公司(自然人独资)
    成立日期:2023-03-02登记机关:聊城高新技术产业开发区管理委员会
    注册地址: 山东省聊城市高新区九州街道长江路北燕山路西华建1街区小区8号商办楼8层8-0810室
    一般项目:化工产品销售(不含许可类化工产品);化肥销售;专用化学产品制造(不含危险化学品);专用化学产品销售(不含危险化学品);饲料添加剂销售;...许可项目:危险化学品经营。(依法须经批准的项目,经相关部门批准后方可开展经营活动,具体经营项目以相关部门批准文件或许可证件为准)
    免费会员展台
    http://www.lcjinxinda.com/
    企业联系电话:18906354373👤
    聊城金信达新材料有限公司
    销售经理: 孙敬彪
    手机:18906354373
    微信:18906354373
    E-mail:sunjingbiao1@sina.com
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    山东省聊城市高新区九州街道长江路北燕山路西华建1街区小区8号商办楼8层8-0810室
    常规和库存产品*产品总量: 912

    平台资质认证✓营业执照✓危化许可证
    产品编号:A0687
    毒毛旋花苷G
    产品图片质量标准: 国标
    包装形式: 可定制包装
    主打产品,精细化学品、医药中间体、材料中间体
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Fuerstenwerth H. On the differences between ouabain and digitalis glycosides. Am J Ther. 2014 Jan-Feb;21(1):35-42. doi: 10.1097/MJT.0b013e318217a609. Review. doi: 10.1007/s11596-014-1236-x. Epub 2014 Feb 6. doi: 10.1089/neu.2014.3544. Epub 2014 Oct 10.
    4: Ninsontia C, Chanvorachote P. Ouabain mediates integrin switch in human lung cancer cells. Anticancer Res. 2014 Oct;34(10):5495-502. doi: 10.1161/HYPERTENSIONAHA.114.03919. Epub 2014 Jul 7. Review. doi: 10.1096/fj.14-252684. Epub 2014 Jun 26.
    8: Dvela M, Rosen H, Ben-Ami HC, Lichtstein D. Endogenous ouabain regulates cell viability. Am J Physiol Cell Physiol. 2012 Jan 15;302(2):C442-52. doi: 10.1152/ajpcell.00336.2011. Epub 2011 Oct 26. English, Russian. Epub 2011 Aug 19. Review. doi: 10.1016/B978-0-12-394305-7.00002-1. Review. doi: 10.1016/j.ejphar.2012.08.004. Epub 2012 Aug 30. doi: 10.1111/j.1365-2869.2009.00781.x. Epub 2009 Oct 28.

    合成参考文献


    摘要:S10 | SWISSPHARMA | Pharmaceutical List with Consumption Data | DOI:10.5281/zenodo.2623484
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知